EHA 2021 | Key targets and the future of immunotherapy in AML
Eunice Wang
• 27 May 2021
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, outlines the role of immunotherapy in the treatment of acute myeloid leukemia (AML), highlighting data on PD-L1 and anti-CTLA4 immune checkpoint inhibitors and novel immunotherapies such as the CD47-targeted antibody magrolimab, which has shown promising data in combination with azacitidine in patients with high-risk myelodysplastic syndromes (MDS) and AML. Dr Wang also comments on the use of anti-TM3 and anti-CD7 antibodies, bispecific antibodies and flotetuzumab, as well as the potential to find therapies which can achieve undetectable measurable residual disease in AML. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
